retatrutide fat loss clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide TRIUMPH-1 Results: 28% Weight

FDA guidance on compounding continues evolving

Its an amylin receptor agonist, functioning as a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells

Clinical Trial Status: Where Each Compound Stands in 2026 Tirzepatide (Fully Approved) Tirzepatide completed its regulatory journey and received: FDA approval as Mounjaro (2022) for type 2 diabetes management FDA approval as Zepbound (2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities It is available via prescription from licensed healthcare providers in the United States and many other countries

The key difference is that retatrutide provides triple agonism (GLP-1 + GIP + glucagon) while semaglutide provides only GLP-1 agonism